Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   42732   clinical trials with a EudraCT protocol, of which   7035   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .

    Clinical Trials marked as "Trial now transitioned" were transitioned to the Clinical Trial Regulation 536/2014 and can be further followed in the Clinical Trial Information System  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    NIRTURE - A Randomised Trial of Early Insulin Therapy in Very Low Birth Weight Infants

    Summary
    EudraCT number
    2004-002170-34
    Trial protocol
    ES  
    Global end of trial date
    15 Feb 2010

    Results information
    Results version number
    v1(current)
    This version publication date
    08 Jul 2016
    First version publication date
    31 Jul 2015
    Other versions
    Summary report(s)
    SAE and AE Listing

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    15/1/04
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    -
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Cambridge Univeristy Hospitals NHS foundation Trust
    Sponsor organisation address
    R&D office Box 146, Addenbrookes NHS Trust, Cambridge, United Kingdom, CB0 0QQ
    Public contact
    Diane Picton , Cambridge University Hospitals NHS Foundation Trust , 44 1223762944, dp223@medschl.cam.ac.uk
    Scientific contact
    Dr Kathy Bearsdall , Cambridge University Hospitals NHS Foundation Trust , 44 1223746791, kb274@medschl.cam.ac.uk
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    30 Oct 2008
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    26 Nov 2007
    Global end of trial reached?
    Yes
    Global end of trial date
    15 Feb 2010
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To evaluate the effect of early fixed dose insulin on mortality in very low birth weight babies
    Protection of trial subjects
    Regular reporting of SAE’s and meetings held yearly
    Background therapy
    Insulin aspart with variable rate 20% dextrose support, Dose 0.05 units/kg/hour, Route of administration Continuous intravenous infusion in the first week of life
    Evidence for comparator
    Standard care
    Actual start date of recruitment
    04 Feb 2005
    Long term follow-up planned
    Yes
    Long term follow-up rationale
    Scientific research
    Long term follow-up duration
    24 Months
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Spain: 25
    Country: Number of subjects enrolled
    United Kingdom: 108
    Country: Number of subjects enrolled
    Belgium: 211
    Country: Number of subjects enrolled
    Netherlands: 45
    Worldwide total number of subjects
    389
    EEA total number of subjects
    389
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    389
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    0
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    Very low birth weight infants (<1500g) were recruited from neonatal intensive care units and randomised to receive either a continuous infusion of insulin (0.05 u/kg/hr) from within 24 hours of birth and for the first 7 days of life, or to act as controls and receive standard neonatal care. Recuitment opened in Feb 2005 & closed June/July 2007.

    Pre-assignment
    Screening details
    Screening for eligibility was performed in conjunction with the clinical team

    Period 1
    Period 1 title
    Start-end of study intervention (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Intervention
    Arm description
    Early fixed dose insulin replacement
    Arm type
    Experimental

    Investigational medicinal product name
    Insulin Aspart
    Investigational medicinal product code
    Other name
    Novorapid
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Intravenous use
    Dosage and administration details
    0.05u/kg/hr

    Arm title
    Control
    Arm description
    Standard care
    Arm type
    Standard Care

    Investigational medicinal product name
    No investigational medicinal product assigned in this arm
    Number of subjects in period 1
    Intervention Control
    Started
    195
    194
    Completed
    194
    192
    Not completed
    1
    2
         Adverse event, serious fatal
    1
    -
         Consent withdrawn by subject
    -
    2

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Intervention
    Reporting group description
    Early fixed dose insulin replacement

    Reporting group title
    Control
    Reporting group description
    Standard care

    Reporting group values
    Intervention Control Total
    Number of subjects
    195 194 389
    Age categorical
    Units: Subjects
        In utero
    0 0 0
        Preterm newborn infants (gestational age < 37 wks)
    194 192 386
        Newborns (0-27 days)
    0 0 0
        Infants and toddlers (28 days-23 months)
    0 0 0
        Children (2-11 years)
    0 0 0
        Adolescents (12-17 years)
    0 0 0
        Adults (18-64 years)
    0 0 0
        From 65-84 years
    0 0 0
        85 years and over
    0 0 0
        Not recorded
    1 2 3
    Age continuous
    Units: weeks
        arithmetic mean (standard deviation)
    27.6 ± 2.2 27.8 ± 2.2 -
    Gender categorical
    Units: Subjects
        Female
    101 95 196
        Male
    94 99 193
    Receipt of Antenatal glucocorticoids
    Units: Subjects
        yes
    178 176 354
        no
    16 16 32
        not recorded
    1 2 3
    Birth Weight
    Birth Weight
    Units: kg
        arithmetic mean (standard deviation)
    1.007 ± 0.267 1.009 ± 0.274 -
    Head Circumference
    Units: cm
        arithmetic mean (standard deviation)
    25.3 ± 2.2 25.4 ± 2.3 -
    Crown Heel Length
    Units: cm
        arithmetic mean (standard deviation)
    35.3 ± 3.7 35.4 ± 3.6 -
    Birth Weight SDS
    Units: SDS
        arithmetic mean (standard deviation)
    -0.84 ± 1.1 -0.91 ± 1.1 -
    CRIB score
    Units: number
        arithmetic mean (standard deviation)
    3.99 ± 3.5 4.02 ± 3.4 -

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Intervention
    Reporting group description
    Early fixed dose insulin replacement

    Reporting group title
    Control
    Reporting group description
    Standard care

    Primary: Death on or before expected date of delivery (taken as date considered to be the most accurate estimate of delivery date).

    Close Top of page
    End point title
    Death on or before expected date of delivery (taken as date considered to be the most accurate estimate of delivery date).
    End point description
    End point type
    Primary
    End point timeframe
    Death on or before expected date of delivery (taken as date considered to be the most accurate estimate of delivery date).
    End point values
    Intervention Control
    Number of subjects analysed
    195
    194
    Units: subjects
        Death before expected date of delivery
    28
    18
        Alive at expected date of delivery
    166
    174
        Not Recorded
    1
    2
    Statistical analysis title
    Death before expected delivery date
    Statistical analysis description
    Fisher's exact test applied to the frequency table cross-classifying the binary endpoint (death before expected deliver date) against treatment arm
    Comparison groups
    Intervention v Control
    Number of subjects included in analysis
    389
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.2
    Method
    Fisher exact
    Parameter type
    Odds ratio (OR)
    Point estimate
    0.61
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.33
         upper limit
    1.15

    Adverse events

    Close Top of page
    Adverse events information [1]
    Timeframe for reporting adverse events
    24 hours
    Assessment type
    Non-systematic
    Dictionary used for adverse event reporting
    Dictionary name
    Protocol Based
    Dictionary version
    1
    Frequency threshold for reporting non-serious adverse events: 0%
    Notes
    [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.
    Justification: A listing of serious adverse events are given in an attachment

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    15 Oct 2004
    Protocol changes post original submission
    25 Nov 2004
    Change in Trial stastistician ,Secondary Endpoints and randomsiation procedure.
    17 Jun 2005
    Change of Trial Statistician and DMC Statistician to ensure independence. Revised study documentation
    11 Jan 2006
    Justification to allow recruitment to multiple trial
    19 Apr 2006
    Follow up plans - Appendix 3 (follow-up protocol). Patient information sheets and consent forms V2 ( April 2006)
    25 Jun 2006
    Change of PI
    03 Apr 2007
    Plans to follow-up participants through Office of National Stastistic (ONS)
    15 Aug 2007
    Recruitment suspended
    13 Sep 2007
    Recruitment stopped on ground of futility
    20 Jun 2008
    Specifically requesting cause of death
    06 Sep 2009
    Change of Sponsor. Sent in for notification only but reviewed formally by ethic committee

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported

    Online references

    http://www.ncbi.nlm.nih.gov/pubmed/18971490
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2022 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA